Overview
MDM2 is a protein that helps control the levels of p53, a major tumor suppressor often called the cell’s “guardian of the genome.” In many cancers, including acute myeloid leukemia (AML), p53 itself is not mutated. Instead, its activity is switched off by excess MDM2, which leads to reduced tumor-suppressing function. This has made MDM2 an attractive treatment target in leukemias with wild-type TP53.
A major challenge with direct MDM2 inhibitors is that when they stabilize p53, they can also trigger a compensatory rise in MDM2. That feedback loop can weaken the drug’s effect and limit long-term benefit. This study examined whether a PROTAC-based MDM2 degrader could overcome that problem by removing the MDM2 protein rather than simply blocking it.
